The Global Use of Medicines - IMS Health
The Global Use of Medicines - IMS Health
The Global Use of Medicines - IMS Health
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Appendix 4<br />
Leading therapy classes in 2015<br />
Oncology $75-80Bn 5-8%<br />
Antidiabetics<br />
$43-48Bn 4-7%<br />
Respiratory<br />
$41-46Bn 2-5%<br />
Lipid regulators<br />
$29-34Bn -2 to -5%<br />
Angiotensin inhibitors<br />
$28-33Bn<br />
1-4%<br />
Autoimmune $27-32Bn<br />
6-9%<br />
HIV antivirals $20-24Bn<br />
5-8%<br />
Antipsychotics $18-22Bn<br />
-3 to -6%<br />
Platelet aggregation inhibitors $18-22Bn<br />
4-7%<br />
Anti-ulcerants $18-22Bn<br />
-5 to -8%<br />
Antidepressants $13-16Bn<br />
-5 to -8%<br />
Anti-epileptics $13-16Bn<br />
1-4%<br />
Multiple sclerosis $12-15Bn<br />
5-8%<br />
Osteoporosis $11-13Bn<br />
8-11%<br />
Narcotic analgesics $10-12Bn<br />
0 to -3%<br />
Attention Deficit Hyperactivity Disorder $9-11Bn<br />
4-7%<br />
Erythropoeisis Disorder stimulating agents $9-11Bn<br />
0 to -3%<br />
Alzheimer's $9-11Bn<br />
1-4%<br />
Antivirals excl. HIV $8-10Bn<br />
1-4%<br />
Glaucoma $5-6Bn<br />
0 to -3%<br />
0 10 20 30 40 50 60 70 80 90<br />
Source: <strong>IMS</strong> Institute for <strong>Health</strong>care Informatics; <strong>The</strong>rapy Forecaster, May 2011<br />
Appendix notes<br />
All spending and growth in US$ with constant<br />
exchange rates.<br />
<strong>The</strong> <strong>Global</strong> <strong>Use</strong> <strong>of</strong> <strong>Medicines</strong>: Outlook Through 2015<br />
Report by the <strong>IMS</strong> Institute for <strong>Health</strong>care Informatics<br />
26
Change language